RNXT
RenovoRx, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.39
+0.84%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- 63.68x
- P/S forward
- 16.94x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 12.01x
- Price / sales
- 54.58x
- Price / cash flow
- -9.09x
Enterprise value
- Enterprise value
- $98.6M
- EV / sales
- 49.92x
- EV / EBITDA
- -8.03x
- EV / EBIT
- -7.36x
- Market cap
- $107.9M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026